Cytokinetics (CYTK) Tops Q4 EPS by 43c
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $82.01 -3.37%
EPS Growth %: -45.5%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
CCEL, MHGU, PLG, More
EPS Growth %: -45.5%
Financial Fact:
License revenues from related parties: 53.03M
Today's EPS Names:
CCEL, MHGU, PLG, More
Join SI Premium – FREE
Cytokinetics (NASDAQ: CYTK) reported Q4 basic EPS of $0.16, $0.43 better than the analyst estimate of ($0.27), may not compare. Revenue for the quarter came in at $33.1 million versus the consensus estimate of $16.33 million.
GUIDANCE:
Cytokinetics sees FY 2017 cash revenue of $21-23 million.
For earnings history and earnings-related data on Cytokinetics (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
- Truist upgrades Biogen to Buy on Alzheimer's, pipeline optimism ahead of key data
- Hillman Solutions launches $1.1B debt refinancing, reports Q2 sales
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
